HK1218254A1 - 用拉喹莫德治疗多发性硬化症 - Google Patents

用拉喹莫德治疗多发性硬化症 Download PDF

Info

Publication number
HK1218254A1
HK1218254A1 HK16106269.3A HK16106269A HK1218254A1 HK 1218254 A1 HK1218254 A1 HK 1218254A1 HK 16106269 A HK16106269 A HK 16106269A HK 1218254 A1 HK1218254 A1 HK 1218254A1
Authority
HK
Hong Kong
Prior art keywords
laquinimod
multiple sclerosis
progressive
subject
amount
Prior art date
Application number
HK16106269.3A
Other languages
English (en)
Chinese (zh)
Inventor
Tarcic Nora
Bar-Zohar Dan
Hayardeny Liat
Gilgun Sherki Yossi
Gorfine Tali
Knappertz Volker
Sorani Ella
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51351655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1218254(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of HK1218254A1 publication Critical patent/HK1218254A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
HK16106269.3A 2013-02-15 2014-02-13 用拉喹莫德治疗多发性硬化症 HK1218254A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361765394P 2013-02-15 2013-02-15
US61/765,394 2013-02-15
US201361911106P 2013-12-03 2013-12-03
US61/911,106 2013-12-03
PCT/US2014/016278 WO2014127139A1 (en) 2013-02-15 2014-02-13 Treatment of multiple sclerosis with laquinimod

Publications (1)

Publication Number Publication Date
HK1218254A1 true HK1218254A1 (zh) 2017-02-10

Family

ID=51351655

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16106269.3A HK1218254A1 (zh) 2013-02-15 2014-02-13 用拉喹莫德治疗多发性硬化症
HK16106220.1A HK1218251A1 (zh) 2013-02-15 2014-02-13 用拉喹莫德治疗多发性硬化症

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16106220.1A HK1218251A1 (zh) 2013-02-15 2014-02-13 用拉喹莫德治疗多发性硬化症

Country Status (18)

Country Link
US (2) US20140235670A1 (https=)
EP (1) EP2956137A4 (https=)
JP (1) JP2016510343A (https=)
KR (1) KR20150119227A (https=)
CN (1) CN105163737A (https=)
AU (1) AU2014216199A1 (https=)
BR (1) BR112015019564A2 (https=)
CA (1) CA2900503A1 (https=)
CL (1) CL2015002181A1 (https=)
EA (1) EA201591507A1 (https=)
HK (2) HK1218254A1 (https=)
IL (1) IL240014A0 (https=)
MX (1) MX2015010296A (https=)
PE (1) PE20151526A1 (https=)
SG (1) SG11201505818WA (https=)
TW (1) TW201442709A (https=)
UY (1) UY35328A (https=)
WO (1) WO2014127139A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104093310A (zh) 2012-02-03 2014-10-08 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
AR090885A1 (es) * 2012-05-02 2014-12-10 Teva Pharma Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
WO2015168103A1 (en) * 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
CN114699409A (zh) * 2014-10-16 2022-07-05 诺华股份有限公司 包含辛波莫德和拉喹莫德的用于治疗多发性硬化症的组合
US10091217B2 (en) 2016-06-21 2018-10-02 Logrhythm, Inc. Risk based priority processing of data
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
CN110382052A (zh) * 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
US20230296628A1 (en) * 2020-07-09 2023-09-21 Oklahoma Medical Research Foundation Biomarkers for Identifying Relapses in Multiple Sclerosis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
KR20150065951A (ko) * 2006-06-12 2015-06-15 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
US8138201B2 (en) * 2007-07-11 2012-03-20 Medicinova, Inc. Treatment of progressive neurodegenerative disease with ibudilast
AR073295A1 (es) * 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
US20110268699A1 (en) * 2008-12-11 2011-11-03 Biovista, Inc. Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles
JP2012530701A (ja) * 2009-06-19 2012-12-06 テバ ファーマシューティカル インダストリーズ リミティド 多発性硬化症のラキニモドでの治療
AU2011338647A1 (en) * 2010-12-07 2013-07-04 Teva Pharmaceutical Industries Ltd. Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
AU2012286701A1 (en) * 2011-07-28 2014-03-06 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and interferon-beta
AR090885A1 (es) * 2012-05-02 2014-12-10 Teva Pharma Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
BR112015007782A2 (pt) * 2012-10-12 2017-07-04 Teva Pharma laquinimod para reduzir danos talâmicos na esclerose múltipla
WO2015168103A1 (en) * 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status

Also Published As

Publication number Publication date
UY35328A (es) 2014-09-30
CN105163737A (zh) 2015-12-16
EA201591507A1 (ru) 2015-12-30
HK1218251A1 (zh) 2017-02-10
EP2956137A1 (en) 2015-12-23
CA2900503A1 (en) 2014-08-21
WO2014127139A1 (en) 2014-08-21
BR112015019564A2 (pt) 2017-07-18
SG11201505818WA (en) 2015-08-28
US20140235670A1 (en) 2014-08-21
CL2015002181A1 (es) 2016-06-03
TW201442709A (zh) 2014-11-16
IL240014A0 (en) 2015-09-24
KR20150119227A (ko) 2015-10-23
MX2015010296A (es) 2016-05-05
PE20151526A1 (es) 2015-11-20
AU2014216199A1 (en) 2015-09-03
US20180064702A1 (en) 2018-03-08
EP2956137A4 (en) 2016-08-03
JP2016510343A (ja) 2016-04-07

Similar Documents

Publication Publication Date Title
HK1218254A1 (zh) 用拉喹莫德治疗多发性硬化症
CN103260624B (zh) 拉喹莫德用于在多发性硬化症患者中减少疲劳、改善功能状态和改善生活品质的用途
DK2442651T3 (en) Treatment of multiple sclerosis with laquinimod
HK1226940A1 (zh) 用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症
US20160296511A1 (en) Laquinimod for reducing thalamic damage in multiple sclerosis
EP2844255A1 (en) Use of high dose laquinimod for treating multiple sclerosis
AU2015253330A1 (en) Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
HK1224555A1 (en) Use of high dose laquinimod for treating multiple sclerosis
TW201404395A (zh) 以拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）及醋酸格拉替雷（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）之組合治療多發性硬化症